Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.…
Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?
Alto Neuroscience (NYSE: ANRO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 68 employees.
The shares were at 25.37 USD on 20 November 2026, up 119.7% over 52 weeks. Its 52-week range is 10.80 USD to 37.43 USD: the price is 32.2% below the high and 134.9% above the low.
Its market capitalisation is 1.02B USD.
Alto Neuroscience reports return on equity of -41.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 301.32M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 38.67 USD is 52.4% above the current price. The next earnings report is expected on 15 March 2027.